In this study, patients undergoing PD-1 inhibitor therapy for advanced non-small cell lung cancer (ANSCLC) were classified into an Observation Group (OG, n=92) with adverse reactions (ARs) and a Control Group (CG, n=123) without ARs. Here, PDCD1 is linked to non-small cell lung carcinoma.